Developer docs
API playgroundTry for free, no card

Search company profiles

Octapharma Plasma

Full company profile

uuid00065xe

Namestring
Octapharma Plasma
Legal namestring
Octapharma Plasma, Inc.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Octapharma Plasma, Inc. (OPI) is the US plasma-collection subsidiary of Swiss pharmaceutical group Octapharma AG. Headquartered in Charlotte, North Carolina, OPI operates more than 180 physical plasma donation centers across the United States where adult donors contribute plasma via automated plasmapheresis and receive financial compensation. The company reports a workforce of approximately 4,906 employees (firmographic band 5,001-10,000), with leadership disclosure indicating 69% employees of color and 67% women. OPI serves two distinct constituencies: (i) individual plasma donors who supply biological material up to twice weekly, motivated by compensation, flexible scheduling, and altruism, and (ii) downstream patients with rare and chronic conditions such as hemophilia, primary immunodeficiency, autoimmune disorders, and trauma, whose plasma-derived therapies require 130-1,200 donations per patient per year and address over 300 conditions.

The company's product surface spans the physical donation experience and a recently built digital ecosystem. The OctaApp mobile application (iOS and Android) integrates appointment scheduling, OctaPass (online pre-screening questionnaire completed within two hours of donation), OctaRewards (a non-expiring loyalty point program), and access to the web-based Donor Portal. New donors can earn up to $750 in compensation during their first 35 days. Plasma collection is performed using automated plasmapheresis equipment that separates plasma from whole blood and returns red blood cells to the donor; the process takes 45-90 minutes and is repeatable twice weekly with 48-hour intervals.

OPI operates as a captive supply chain for Octapharma AG: plasma is collected from donors and sold internally to the parent for fractionation into immunoglobulins, albumin, and clotting factors. The company is privately held, incorporated in North Carolina, and not publicly traded. Beyond its core collection operation, OPI engages in patient-advocacy partnerships such as with the Ree Wynn Foundation (October 2024) for TTP awareness and runs multi-channel donor acquisition and retention through the OctaApp, website, paid and organic social media, SEO, donor referral programs, and International Plasma Awareness Week events. No AI/ML capabilities, patents, or third-party AI integrations are disclosed.

Short descriptiontext

Octapharma Plasma operates 180+ US plasma donation centers as the collection arm of Octapharma AG, paying individual donors to supply plasma that is fractionated into therapies for 300+ rare and chronic conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersCharlotte, United States
HQ citystring
Charlotte
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
plasma collection services, plasma donation centers, compensated plasma donation, plasma-derived therapies supply, plasmapheresis services
Industry4 codes
PRIMARYHLAIAHAH
Plasma Collection & Donor Services (Plasmapheresis Centers)
SECONDARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAJAJ
Plasma-Derived & Blood Products Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYBPAGACAJ
Blood, Organ & Tissue Donation Organizations
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Plasma Collection Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Plasma Collection and Sale
TypeTransaction Fee
Description

Octapharma Plasma collects plasma from donors and sells it to Octapharma AG (parent company) for manufacturing into plasma-derived therapies. Revenue is generated through compensation paid to donors (treated as cost of goods), with income derived from processed plasma products including immunoglobulins, albumin, and clotting factors.

octapharmaplasma.com
2Donor Compensation
TypeTransaction Fee
Description

Donors receive financial compensation for plasma donations, with new donors able to earn up to $750 during their first 35 days. Compensation varies by location and donation frequency (up to twice weekly).

octapharmaplasma.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D
Pricing details1 tier
1New Donor Compensation - Up to $750 in first 35 days
ModelUnit PricingBilling cadencePer donation
Notes

New donors can earn up to $750 with bonuses during the first 35 days. Based on 10 donations. Payouts vary by location. Compensation amounts vary by location; contact your local donation center to learn more.

octapharmaplasma.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Octapharma Plasma operates a network of 180+ plasma donation centers across the United States where individual donors contribute plasma through automated plasmapheresis in exchange for financial compensation. The collected plasma is supplied to parent company Octapharma AG for manufacturing into plasma-derived therapies that treat more than 300 conditions, including hemophilia, primary immunodeficiency, and autoimmune disorders. New donors can earn up to $750 in compensation during their first 35 days, with donations possible up to twice weekly.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 800,000+ patients helped through plasma-derived therapies
+3 more records
Product overview1 text field

Octapharma Plasma operates a plasma donation network with over 180 centers across the United States. The company offers a unified donor experience centered around the OctaApp mobile application, which serves as the primary digital interface integrating OctaPass (online pre-screening), OctaRewards (loyalty program), and donor account access. The Donor Portal provides complementary web-based functionality for viewing test results and donation history. The core offering is plasma collection services, where donated plasma is processed into therapies treating over 300 conditions including hemophilia, primary immunodeficiency, and chronic inflammatory demyelinating polyneuropathy.

Product and service3 records
1Plasma Donation Services
CategoryPlasma Collection Service
Description

Plasma collection service where donors contribute plasma used to create life-saving therapies for patients with rare and chronic conditions including hemophilia, immune deficiencies, and autoimmune disorders. Donors can earn up to $750 in the first 35 days.

2OctaApp
CategoryMobile Application
Description

Mobile application enabling donors to schedule appointments, access OctaPass for online screening, view payment information, and manage OctaRewards loyalty points. Available on Google Play and Apple App Store.

3Donor Portal
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Ree Wynn Foundation (RWF)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Partnership to raise awareness for Thrombotic Thrombocytopenic Purpura (TTP). During International Plasma Awareness Week October 2024, Octapharma Plasma coordinated its first plasma drive at two donation centers in New Jersey in collaboration with RWF. The foundation educates and promotes TTP awareness to reduce mortality rates and enhance quality of life for those living with this rare blood disorder.

octapharmaplasma.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1BPL Plasma
TypeDirect peer
Description

US paid-plasma collection network operated by Bio Products Laboratory, a global plasma fractionator. Direct competitor in donor acquisition and supplies its parent's fractionation needs.

TypeDirect peer
Description

Plasma collection subsidiary of Takeda operating a large US center network with paid donor compensation. Direct competitor for donors and supplies plasma to its parent's fractionation operations, mirroring Octapharma Plasma's structure.

TypeRegional player
Description

Canadian paid-plasma collection operator with a comparable paid-donor model. Comparable on business model and process but operates in a different regulatory and geographic market than Octapharma Plasma.

TypeDirect peer
Description

US plasma donation network historically tied to Kedrion, operating paid donor centers across multiple states. Direct competitor for donors with the same per-donation compensation structure.

TypeBroad incumbent
Description

Global plasma-derived therapies manufacturer that also operates its own US plasma collection network (e.g., Biomat USA, Talecris Plasma Resources). Comparable because it is both a fractionator and a competitor collector, though broader in scope than Octapharma Plasma.

TypeOthers
Description

Large US nonprofit blood and plasma collector focused on volunteer (unpaid) donations. Not a direct competitor for paid plasma but operates in the adjacent whole-blood/plasma collection ecosystem with overlap in regulatory and operational complexity.

TypeBroad incumbent
Description

Plasma-derived therapeutics manufacturer with collection operations in the US and Europe. Comparable as an integrated collector-frationator, though its collection footprint is smaller and less US-centric than Octapharma Plasma's.

TypeDirect peer
Description

US plasma collection business owned by ADMA Biologics that supplies source plasma for hyperimmune and immunoglobulin therapies. Direct comparator in the paid-donor plasma collection niche.

TypeDirect peer
Description

Largest US paid-plasma collection network and a direct competitor. Operates hundreds of donation centers with the same donor-compensation model and supplies plasma to CSL Behring for fractionation — the closest analogue to Octapharma Plasma's role within Octapharma AG.

TypeRegional player
Description

Paid-plasma collection network focused primarily on Texas and surrounding Sun Belt states. Comparable operating model and donor experience, but more regional in scope than Octapharma Plasma's national footprint.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Octapharma Plasma

Plasma Collection Servicesoctapharmaplasma.com

Octapharma Plasma operates 180+ US plasma donation centers as the collection arm of Octapharma AG, paying individual donors to supply plasma that is fractionated into therapies for 300+ rare and chronic conditions.

What Octapharma Plasma does

Octapharma Plasma, Inc. (OPI) is the US plasma-collection subsidiary of Swiss pharmaceutical group Octapharma AG. Headquartered in Charlotte, North Carolina, OPI operates more than 180 physical plasma donation centers across the United States where adult donors contribute plasma via automated plasmapheresis and receive financial compensation. The company reports a workforce of approximately 4,906 employees (firmographic band 5,001-10,000), with leadership disclosure indicating 69% employees of color and 67% women. OPI serves two distinct constituencies: (i) individual plasma donors who supply biological material up to twice weekly, motivated by compensation, flexible scheduling, and altruism, and (ii) downstream patients with rare and chronic conditions such as hemophilia, primary immunodeficiency, autoimmune disorders, and trauma, whose plasma-derived therapies require 130-1,200 donations per patient per year and address over 300 conditions.

The company's product surface spans the physical donation experience and a recently built digital ecosystem. The OctaApp mobile application (iOS and Android) integrates appointment scheduling, OctaPass (online pre-screening questionnaire completed within two hours of donation), OctaRewards (a non-expiring loyalty point program), and access to the web-based Donor Portal. New donors can earn up to $750 in compensation during their first 35 days. Plasma collection is performed using automated plasmapheresis equipment that separates plasma from whole blood and returns red blood cells to the donor; the process takes 45-90 minutes and is repeatable twice weekly with 48-hour intervals.

OPI operates as a captive supply chain for Octapharma AG: plasma is collected from donors and sold internally to the parent for fractionation into immunoglobulins, albumin, and clotting factors. The company is privately held, incorporated in North Carolina, and not publicly traded. Beyond its core collection operation, OPI engages in patient-advocacy partnerships such as with the Ree Wynn Foundation (October 2024) for TTP awareness and runs multi-channel donor acquisition and retention through the OctaApp, website, paid and organic social media, SEO, donor referral programs, and International Plasma Awareness Week events. No AI/ML capabilities, patents, or third-party AI integrations are disclosed.

Octapharma Plasma firmographics

Firmographics
Name
Octapharma Plasma
Legal name
Octapharma Plasma, Inc.
Website
https://octapharmaplasma.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Octapharma Plasma operates 180+ US plasma donation centers as the collection arm of Octapharma AG, paying individual donors to supply plasma that is fractionated into therapies for 300+ rare and chronic conditions.
Ownership category
akta.pro rank

Octapharma Plasma industry classification

Industry
Product category
Plasma Collection Services
NAICS
Blood and Organ Banks (621991)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAHAH
Plasma Collection & Donor Services (Plasmapheresis Centers)
SECONDARYHLAAAAAI
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAJAJ
Plasma-Derived & Blood Products Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYBPAGACAJ
Blood, Organ & Tissue Donation Organizations

Keywords

  • Plasma collection services
  • Plasma donation centers
  • Compensated plasma donation
  • Plasma-derived therapies supply
  • Plasmapheresis services

Where Octapharma Plasma is headquartered

Location

Headquarters

HQ city
Charlotte
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Octapharma Plasma business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

  1. Plasma Collection and Sale: Octapharma Plasma collects plasma from donors and sells it to Octapharma AG (parent company) for manufacturing into plasma-derived therapies. Revenue is generated through compensation paid to donors (treated as cost of goods), with income derived from processed plasma products including immunoglobulins, albumin, and clotting factors.
  2. Donor Compensation: Donors receive financial compensation for plasma donations, with new donors able to earn up to $750 during their first 35 days. Compensation varies by location and donation frequency (up to twice weekly).

Pricing tiers

ModelBillingPrice
Unit PricingPer donationNew Donor Compensation - Up to $750 in first 35 days

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Octapharma Plasma product offering

Product offering

Core offering

Octapharma Plasma operates a network of 180+ plasma donation centers across the United States where individual donors contribute plasma through automated plasmapheresis in exchange for financial compensation. The collected plasma is supplied to parent company Octapharma AG for manufacturing into plasma-derived therapies that treat more than 300 conditions, including hemophilia, primary immunodeficiency, and autoimmune disorders. New donors can earn up to $750 in compensation during their first 35 days, with donations possible up to twice weekly.

Product overview

Octapharma Plasma operates a plasma donation network with over 180 centers across the United States. The company offers a unified donor experience centered around the OctaApp mobile application, which serves as the primary digital interface integrating OctaPass (online pre-screening), OctaRewards (loyalty program), and donor account access. The Donor Portal provides complementary web-based functionality for viewing test results and donation history. The core offering is plasma collection services, where donated plasma is processed into therapies treating over 300 conditions including hemophilia, primary immunodeficiency, and chronic inflammatory demyelinating polyneuropathy.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plasma Donation Services Plasma collection service where donors contribute plasma used to create life-saving therapies for patients with rare and chronic conditions including hemophilia, immune deficiencies, and autoimmune disorders. Donors can earn up to $750 in the first 35 days.
  • OctaApp Mobile application enabling donors to schedule appointments, access OctaPass for online screening, view payment information, and manage OctaRewards loyalty points. Available on Google Play and Apple App Store.
  • Donor Portal

Quantifiable outcome

  • 800,000+ patients helped through plasma-derived therapies
  • +3 more outcomes

Companies that use Octapharma Plasma

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Octapharma Plasma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Octapharma Plasma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ree Wynn Foundation (RWF)minorStrategic or Co-development Partner · 1 October 2024Partnership to raise awareness for Thrombotic Thrombocytopenic Purpura (TTP). During International Plasma Awareness Week October 2024, Octapharma Plasma coordinated its first plasma drive at two donation centers in New Jersey in collaboration with RWF. The foundation educates and promotes TTP awareness to reduce mortality rates and enhance quality of life for those living with this rare blood disorder.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Octapharma Plasma competitors and assessment

Company assessment

Direct peers

  • BPL Plasma: US paid-plasma collection network operated by Bio Products Laboratory, a global plasma fractionator. Direct competitor in donor acquisition and supplies its parent's fractionation needs.
  • BioLife Plasma Services: Plasma collection subsidiary of Takeda operating a large US center network with paid donor compensation. Direct competitor for donors and supplies plasma to its parent's fractionation operations, mirroring Octapharma Plasma's structure.
  • KEDPlasma: US plasma donation network historically tied to Kedrion, operating paid donor centers across multiple states. Direct competitor for donors with the same per-donation compensation structure.
  • ADMA Biocenters: US plasma collection business owned by ADMA Biologics that supplies source plasma for hyperimmune and immunoglobulin therapies. Direct comparator in the paid-donor plasma collection niche.
  • CSL Plasma: Largest US paid-plasma collection network and a direct competitor. Operates hundreds of donation centers with the same donor-compensation model and supplies plasma to CSL Behring for fractionation — the closest analogue to Octapharma Plasma's role within Octapharma AG.

Regional players

  • Canadian Plasma Resources: Canadian paid-plasma collection operator with a comparable paid-donor model. Comparable on business model and process but operates in a different regulatory and geographic market than Octapharma Plasma.
  • GCAM Plasma: Paid-plasma collection network focused primarily on Texas and surrounding Sun Belt states. Comparable operating model and donor experience, but more regional in scope than Octapharma Plasma's national footprint.

Broad incumbents

  • Grifols: Global plasma-derived therapies manufacturer that also operates its own US plasma collection network (e.g., Biomat USA, Talecris Plasma Resources). Comparable because it is both a fractionator and a competitor collector, though broader in scope than Octapharma Plasma.
  • Kedrion: Plasma-derived therapeutics manufacturer with collection operations in the US and Europe. Comparable as an integrated collector-frationator, though its collection footprint is smaller and less US-centric than Octapharma Plasma's.

Others

  • Vitalant: Large US nonprofit blood and plasma collector focused on volunteer (unpaid) donations. Not a direct competitor for paid plasma but operates in the adjacent whole-blood/plasma collection ecosystem with overlap in regulatory and operational complexity.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Octapharma Plasma social profiles

Digital presence

Octapharma Plasma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Octapharma Plasma leadership team

Management profile

Number of profiles

Profiles7 records

Octapharma Plasma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Octapharma Plasma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Octapharma Plasma

What does Octapharma Plasma do?

Octapharma Plasma operates a network of 180+ plasma donation centers across the United States where individual donors contribute plasma through automated plasmapheresis in exchange for financial compensation. The collected plasma is supplied to parent company Octapharma AG for manufacturing into plasma-derived therapies that treat more than 300 conditions, including hemophilia, primary immunodeficiency, and autoimmune disorders. New donors can earn up to $750 in compensation during their first 35 days, with donations possible up to twice weekly.

Is Octapharma Plasma a public or private company?

Octapharma Plasma is a private company. It is classified as corporate owned and is currently operating.

When was Octapharma Plasma founded?

Octapharma Plasma was founded in 2008. It employs 1,001 to 5,000 people.

Where is Octapharma Plasma based?

Octapharma Plasma is headquartered in Charlotte, United States, in the North America region.

How does Octapharma Plasma make money?

Two revenue lines are on record. Plasma Collection and Sale is the primary driver. The others are donor Compensation.

Who are Octapharma Plasma's main competitors?

Direct peers on record are BPL Plasma, BioLife Plasma Services, KEDPlasma, ADMA Biocenters and CSL Plasma. Regional players are Canadian Plasma Resources and GCAM Plasma. Broad incumbents are Grifols and Kedrion. Vitalant is listed as an others.

Does Octapharma Plasma have an API?

No public API is recorded for Octapharma Plasma.

What industry is Octapharma Plasma in?

Octapharma Plasma's product category is Plasma Collection Services. Its primary akta.pro industry code is HLAIAHAH, Plasma Collection & Donor Services (Plasmapheresis Centers), with a secondary code of HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors). Its NAICS code is 621991 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Philadelphia InquirerSelling blood plasma for money is becoming a side hustle as more Philadelphia-area residents try to make ends meetInflation is driving more Philadelphia-area residents to donate plasma for cash, with lines growing at centers like B Positive and Octapharma. Donors earn $50–$520 per donation, and U.S. plasma production hit a record 62.5 million liters last year. Companies plan to open new sites, including in Maryland and Allentown.American City Business Journals1,500-job Octapharma Plasma HQ project confirmed for Rock HillOctapharma Plasma confirmed a headquarters project in Rock Hill, South Carolina, that is expected to create 1,500 jobs. The project represents York County's largest economic development investment since 2013, with operations slated to begin in the mid-2030s. The article could not be fully accessed due to subscription restrictions.Post and Courier$1.5B deal saved: Rock Hill approves amended tax agreement bringing Octapharma to former Panthers siteThe Rock Hill City Council approved an amended fee in lieu of tax deal on July 23, 2026, which secures a $1.5 billion project to bring Octapharma Plasma's North American corporate headquarters to Rock Hill, South Carolina. The project is expected to create 1,252 new jobs and follows a tumultuous negotiation process involving local government bodies. The city plans to develop the Palmetto Research Park, previously linked to the Carolina Panthers' headquarters proposal.BioSpaceFDA Approves Octapharma’s Octagam® 10% for Adult DermatomyositisThe FDA approved Octagam 10% for adult dermatomyositis, the first IVIg indicated for this condition. The approval follows the ProDERM trial, where 78.7% of patients responded to Octagam 10% versus 43.8% on placebo. The drug is also indicated for chronic immune thrombocytopenic purpura.CnnSeveral people stabbed at Virginia plasma centerSeveral people were stabbed Thursday at an Octapharma Plasma center in Petersburg, Virginia, and one person is in custody. Police Chief Kenneth Miller told WTVR that the investigation is still active.